A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

June 6, 2022

Primary Completion Date

January 17, 2024

Study Completion Date

February 23, 2024

Conditions
Parkinson DiseaseCognitive Dysfunction
Interventions
DRUG

SAGE-718-matching placebo

Oral capsules

DRUG

SAGE-718

Oral capsules

Trial Locations (38)

10019

Sage Investigational Site, New York

11598

Sage Investigational Site, Woodmere

12208

Sage Investigational Site, Albany

14221

Sage Investigational Site, Williamsville

23502

Sage Investigational Site, Virginia Beach

27607

Sage Investigational Site, Raleigh

30030

Sage Investigational Site, Decatur

32127

Sage Investigational Site, Port Orange

32789

Sage Investigational Site, Orlando

33012

Sage Investigational Site, Hialeah

33032

Sage Investigational Site, Miami

33431

Sage Investigational Site, Boca Raton

33486

Sage Investigational Site, Boca Raton

33609

Sage Investigational Site, Tampa

33613

Sage Investigational Site, Tampa

37232

Sage Investigational Site, Nashville

38157

Sage Investigational Site, Memphis

43221

Sage Investigational Site, Columbus

43614

Sage Investigational Site, Toledo

45221

Sage Investigational Site, Cincinnati

53792

Sage Investigational Site, Madison

55425

Sage Investigational Site, Bloomington

60611

Sage Investigational Site, Chicago

66160

Sage Investigational Site, Kansas City

72205

Sage Investigational Site, Little Rock

77030

Sage Investigational Site, Houston

78229

Sage Investigational Site, San Antonio

80113

Sage Investigational Site, Englewood

85351

Sage Investigational Site, Sun City

89106

Sage Investigational Site, Las Vegas

90048

Sage Investigational Site, Los Angeles

90806

Sage Investigational Site, Long Beach

91335

Sage Investigational Site, Reseda

93710

Sage Investigational Site, Fresno

95816

Sage Investigational Site, Sacramento

06066

Sage Investigational Site, Vernon

11794-8121

Sage Investigational Site, Stony Brook

05401

Sage Investigational Site, Burlington

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY